# Faunabio

> Analysis by Optimly for Optimly AI Visibility, in the Optimly AI Brand Index. Last analyzed September 21, 2026.

> Fauna Bio is an AI-driven drug discovery company leveraging genetic data from 100 million years of evolved disease resistance in diverse mammals. Using its exclusive biobank and in-house Convergence™ platform, the company identifies novel therapeutic targets and develops new drugs for human diseases such as obesity, cardiac regeneration, metabolic disorders, and conditions related to muscle preservation, pain tolerance, DNA damage, and fibrosis. They also research human health in space, focusing on preventing muscle/bone loss and protecting against radiation.

- Business Profile: https://optimly.ai/brand/faunabio
- Publisher: Optimly (https://optimly.ai)
- Dataset: Optimly AI Brand Index (https://optimly.ai/brand)
- Official website: https://faunabio.com/
- Logo: https://logo.clearbit.com/faunabio.com
- Slug: faunabio
- Brand Authority Index tier: Emerging
- Category: AI Drug Discovery & Development Platforms
- Last Analyzed: September 21, 2026

## Buyer Intent Signals
Problems: Need for novel therapeutic targets | Challenges in drug discovery | Obesity treatment gaps | Lack of cardiac regeneration in humans | Metabolic disorders (diabetes, obesity-related) | Muscle atrophy and bone loss (e.g., in space) | Radiation damage (e.g., for astronauts) | DNA damage and viral/parasitic resistance | Scarring/fibrosis | Pain management
Solutions: AI-driven drug discovery | Leveraging natural disease resistance | Genetic data analysis | Target identification and scoring | Development of novel therapeutics | Preclinical drug discovery | Animal model research (extreme mammals) | Space health solutions
Comparisons: Fauna Bio vs. traditional drug discovery | Fauna Bio AI platform capabilities | Fauna Bio collaboration opportunities | Fauna Bio research pipeline | Fauna Bio success stories (Lilly partnership)